JP2012512898A - ジペプチド結合薬用剤 - Google Patents
ジペプチド結合薬用剤 Download PDFInfo
- Publication number
- JP2012512898A JP2012512898A JP2011542481A JP2011542481A JP2012512898A JP 2012512898 A JP2012512898 A JP 2012512898A JP 2011542481 A JP2011542481 A JP 2011542481A JP 2011542481 A JP2011542481 A JP 2011542481A JP 2012512898 A JP2012512898 A JP 2012512898A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- group
- aryl
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(*)(C(C)=Cl)N(*)C(C(*)(*)*)=O Chemical compound CC(*)(C(C)=Cl)N(*)C(C(*)(*)*)=O 0.000 description 7
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13922708P | 2008-12-19 | 2008-12-19 | |
US61/139,227 | 2008-12-19 | ||
PCT/US2009/068711 WO2010080605A1 (en) | 2008-12-19 | 2009-12-18 | Dipeptide linked medicinal agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015181062A Division JP2016028082A (ja) | 2008-12-19 | 2015-09-14 | ジペプチド結合薬用剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012512898A true JP2012512898A (ja) | 2012-06-07 |
JP2012512898A5 JP2012512898A5 (zh) | 2013-02-14 |
Family
ID=42316744
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011542481A Withdrawn JP2012512898A (ja) | 2008-12-19 | 2009-12-18 | ジペプチド結合薬用剤 |
JP2015181062A Pending JP2016028082A (ja) | 2008-12-19 | 2015-09-14 | ジペプチド結合薬用剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015181062A Pending JP2016028082A (ja) | 2008-12-19 | 2015-09-14 | ジペプチド結合薬用剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20110237493A1 (zh) |
EP (1) | EP2376098A4 (zh) |
JP (2) | JP2012512898A (zh) |
KR (1) | KR20110114568A (zh) |
CN (1) | CN102300580A (zh) |
AU (1) | AU2009335711A1 (zh) |
CA (1) | CA2747195A1 (zh) |
IL (1) | IL213341A0 (zh) |
MX (1) | MX2011006527A (zh) |
PE (1) | PE20120331A1 (zh) |
RU (1) | RU2578591C2 (zh) |
SG (1) | SG172290A1 (zh) |
WO (1) | WO2010080605A1 (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2507098T3 (es) | 2005-11-07 | 2014-10-14 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
MX2009006564A (es) | 2007-01-05 | 2009-06-26 | Univ Indiana Res & Tech Corp | Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. |
WO2008101017A2 (en) | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
CA2713348C (en) | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
WO2009155258A2 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
CA2727161A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
AR074811A1 (es) | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
JP6050746B2 (ja) | 2010-05-13 | 2016-12-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド |
MX2012013001A (es) | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas. |
EP2582719B1 (en) | 2010-06-16 | 2016-08-10 | Indiana University Research and Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
JP6101202B2 (ja) * | 2010-06-24 | 2017-03-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | ジペプチド結合医薬剤 |
JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
AU2012273365A1 (en) | 2011-06-22 | 2014-01-16 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
JP6179864B2 (ja) | 2011-06-22 | 2017-08-16 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン/glp−1レセプタコ−アゴニスト |
US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
CN104114183A (zh) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
CN103172726B (zh) * | 2011-12-22 | 2017-06-13 | 杭州淳泰科技有限公司 | 胰泌素类似物及其制备方法和用途 |
WO2013127779A1 (en) | 2012-03-01 | 2013-09-06 | Novo Nordisk A/S | Glp-1 prodrugs |
ES2602486T3 (es) | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
JP6387008B2 (ja) | 2012-09-26 | 2018-09-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | インスリンアナローグダイマー |
AU2014241743B2 (en) | 2013-03-14 | 2018-07-05 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
CN105934257B (zh) | 2013-12-06 | 2020-10-09 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
EP3206710B1 (en) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Incretin-insulin conjugates |
EP3197912B1 (en) | 2014-09-24 | 2023-01-04 | Indiana University Research & Technology Corporation | Lipidated amide-based insulin prodrugs |
EP3464336B1 (en) | 2016-06-01 | 2022-03-16 | Athira Pharma, Inc. | Compounds |
JP2023527356A (ja) * | 2020-05-26 | 2023-06-28 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 副甲状腺機能低下症を処置するためのpth類似体 |
IL299701A (en) | 2020-07-22 | 2023-03-01 | Novo Nordisk As | GLP-1 and GIP receptor co-agonists suitable for oral administration |
AU2021374823A1 (en) | 2020-11-06 | 2023-05-25 | Novo Nordisk A/S | Glp-1 prodrugs and uses hereof |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
WO2023217744A1 (en) | 2022-05-10 | 2023-11-16 | Novo Nordisk A/S | Prodrugs of glp-1 polypeptide and uses thereof |
WO2024110614A1 (en) | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3740385A (en) * | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
DK119785D0 (da) * | 1985-03-15 | 1985-03-15 | Nordisk Gentofte | Insulinpraeparat |
US4741897A (en) * | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
ES2225107T3 (es) * | 1999-03-29 | 2005-03-16 | Uutech Limited | Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes. |
AUPQ661800A0 (en) * | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
GB2382346B (en) * | 2000-08-04 | 2004-08-11 | Dmi Biosciences Inc | Method of synthesizing diketopiperazines |
EP2295450B1 (en) * | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
EP1243276A1 (en) * | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
ES2464532T3 (es) * | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
JP2005508895A (ja) * | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Glp−1および基礎インスリンの予備混合物 |
US7238656B2 (en) * | 2001-08-29 | 2007-07-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Protective factors against inflammation, burns and noxious stimuli |
CA2468100A1 (en) * | 2001-12-20 | 2003-07-03 | Eli Lilly And Company | Insulin molecule having protracted time action |
FR2842209B1 (fr) * | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
US7557183B2 (en) * | 2003-03-19 | 2009-07-07 | Eli Lilly And Company | Polyethylene glycol linked GLP-1 compounds |
WO2004089280A2 (en) * | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
SI2932981T1 (sl) * | 2003-09-19 | 2021-11-30 | Novo Nordisk A/S | Albumin-vezavni derivati GLP-1 |
WO2005035003A2 (en) * | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
EP1929030A2 (en) * | 2005-09-08 | 2008-06-11 | Shire LLC | Prodrugs of t3 and t4 with enhanced bioavailability |
WO2007109354A2 (en) * | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
WO2008030558A2 (en) * | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
WO2008101017A2 (en) * | 2007-02-15 | 2008-08-21 | Indiana Unversity Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
CA2713348C (en) * | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
AR074811A1 (es) * | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
-
2009
- 2009-12-18 KR KR1020117016192A patent/KR20110114568A/ko not_active Application Discontinuation
- 2009-12-18 MX MX2011006527A patent/MX2011006527A/es active IP Right Grant
- 2009-12-18 US US13/130,963 patent/US20110237493A1/en not_active Abandoned
- 2009-12-18 AU AU2009335711A patent/AU2009335711A1/en not_active Abandoned
- 2009-12-18 RU RU2011129764/04A patent/RU2578591C2/ru not_active IP Right Cessation
- 2009-12-18 SG SG2011045275A patent/SG172290A1/en unknown
- 2009-12-18 JP JP2011542481A patent/JP2012512898A/ja not_active Withdrawn
- 2009-12-18 EP EP09837981.1A patent/EP2376098A4/en not_active Withdrawn
- 2009-12-18 PE PE2011001237A patent/PE20120331A1/es not_active Application Discontinuation
- 2009-12-18 WO PCT/US2009/068711 patent/WO2010080605A1/en active Application Filing
- 2009-12-18 CN CN2009801518123A patent/CN102300580A/zh active Pending
- 2009-12-18 CA CA2747195A patent/CA2747195A1/en not_active Abandoned
-
2011
- 2011-06-02 IL IL213341A patent/IL213341A0/en unknown
-
2015
- 2015-09-14 JP JP2015181062A patent/JP2016028082A/ja active Pending
Non-Patent Citations (2)
Title |
---|
JPN6014020973; Tetrahedron Vol.62, No.48, 20061127, p.11245-11266 * |
JPN6014020983; DE, Arnab: 'Design of Peptide-Based Prodrug Chemistry and Its Application to Glucagon-like Peptide I' IUScholarWorks Repository Home->Chemistry Department (Bloomington)->Master's Theses - Chemistry, [on , 2007 * |
Also Published As
Publication number | Publication date |
---|---|
MX2011006527A (es) | 2011-08-17 |
CN102300580A (zh) | 2011-12-28 |
RU2011129764A (ru) | 2013-01-27 |
IL213341A0 (en) | 2011-07-31 |
JP2016028082A (ja) | 2016-02-25 |
KR20110114568A (ko) | 2011-10-19 |
CA2747195A1 (en) | 2010-07-15 |
PE20120331A1 (es) | 2012-04-14 |
AU2009335711A1 (en) | 2010-07-15 |
SG172290A1 (en) | 2011-07-28 |
US20110237493A1 (en) | 2011-09-29 |
RU2578591C2 (ru) | 2016-03-27 |
EP2376098A1 (en) | 2011-10-19 |
EP2376098A4 (en) | 2014-06-11 |
WO2010080605A1 (en) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012512898A (ja) | ジペプチド結合薬用剤 | |
US20130137849A1 (en) | Dipeptide linked medicinal agents | |
TWI489992B (zh) | 醯胺系胰高血糖素超級家族之胜肽前驅藥物 | |
RU2580317C2 (ru) | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов | |
CA2713348C (en) | Ester-based peptide prodrugs | |
KR102066987B1 (ko) | 폴리펩티드 | |
EP3510044B1 (en) | Amylin analogues | |
EP3271381B1 (en) | Amylin analogues | |
JP2016521253A (ja) | 持続性作用を有するプロドラッグ | |
EP2838914B1 (en) | Human amylin analogues | |
KR20060135661A (ko) | 신규 glp-1 화합물 | |
JP2012512900A (ja) | インスリン受容体に対して高い活性を示すyl系インスリン様増殖因子 | |
WO2022129311A1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121218 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140527 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140821 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140828 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140929 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141006 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141027 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141127 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150914 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20151104 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20151127 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20170104 |